Table 7 Association of level of MSI with dMMR status in the cancer cohort
MSI-H | MSI-H | MSI-H | MSI-H | MSI-L | |
|---|---|---|---|---|---|
Altered markers | 5 | 4 | 3 | 2 | 1 |
All cancers | |||||
MSI (147) | 56 (38.1%) | 21 (14.3%) | 5 (3.4%) | 9 (6.1%) | 56(38.1%) |
dMMR (100) | 53 (53.0%) | 19 (19.0%) | 4 (4.0%) | 6 (6.0%) | 18 (18.0%) |
Colorectal | |||||
MSI (114) | 46 (40.4%) | 18 (15.8%) | 3 (2.6%) | 4 (3.5%) | 43 (37.7%) |
dMMR (67) | 44 (56.4%) | 16 (20.5%) | 3 (3.8%) | 2 (2.6%) | 13 (16.7%) |
Non-colorectal | |||||
MSI (33) | 10 (30.3%) | 3 (9.1%) | 2 (6.1%) | 5 (15.2%) | 13 (39.4%) |
dMMR (22) | 9 (40.9%) | 3 (13.6%) | 1 (4.5%) | 4 (18.2%) | 5 (22.7%) |